Equity Field Notes from temporal sources

[DanWebzster]

VSTM 's lymphoma drug was granted priority review on 4/9/18

PDUFA date = 10/5/18

Duvelisib is differentiated by oral convenience combined with relative efficacy for refractory patients.

Cash at the end of the last reported Q = $82mn This provides a runway into H-1/19. An equity offering is a possibility during 2018.

One theory on VSTM's lagging valuation is that the lymphoma therapy space is in flux. Imbruvica may be dethroned by AZN's Calquence. Several Combo therapies are being tested. It takes much diligence
to keep on top of all this flux.

I would strongly consider take a starter position after an equity offering.